Curatis Holding AG Advances Corticorelin to Phase 3 After Positive FDA Meeting

Curatis Holding AG has announced a positive outcome from its recent meeting with the FDA concerning the clinical development of corticorelin. The official minutes confirm that the company can proceed with its plans for Phase 3 trials of the drug, aimed at treating peritumoral brain edema (PTBE) associated with metastatic brain tumors.

The meeting addressed various aspects of the clinical plan, including Chemistry, Manufacturing and Control, and clinical strategies. The green light for progression marks a significant step forward, facilitating potential partnerships with global oncology leaders.

Corticorelin aims to reduce or replace steroid use in PTBE patients, potentially improving quality of life by addressing steroid-related toxicities. Though promising, the drug remains investigational and is not yet approved for use.